PF-Atlas › Clinical Trials › NCT02951429
Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis and Intermediate or High Probability of Group 3 Pulmonary Hypertension
Pirfenidone · Phase 2
Registry ID
NCT02951429
Phase
Phase 2
Status
Completed
Drug / intervention
Pirfenidone
Sponsor
Hoffmann-La Roche
Start
2016-12-31
Enrollment
177
Locations
56
About this trial
This Phase IIb, randomized, placebo-controlled, multicenter, international study will evaluate the efficacy, safety, and tolerability of sildenafil or placebo added to pirfenidone (Esbriet) treatment in participants with advanced IPF and intermediate or high probability of Group 3 pulmonary hypertension (PH) who are on a stable dose of pirfenidone with demonstrated tolerability. Participants will be randomized to receive 1 year of treatment with either oral sildenafil or matching placebo while continuing to take pirfenidone.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02951429 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.